

# ■ General Information

## **Applications**

- **Immunohistochemistry**
- TUNEL for apoptosis In situ hybridization (ISH)
  - mRNA
  - miRNA
  - Fluorescent In situ hybridization (FISH)

### Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

#### How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  Cleared by xylene, three changes for 1 hour each.
  Infiltrated with 60°C paraffin, three changes for 1 hour each

- Sectioned by microtome in 4 µm thickness

#### Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times. Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

#### Slide orientation

In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

1	2	3	4	5	6	7	8	9	10
11	12	13	14	15	16	17	18	19	20
21	22	23	24	25	26	27	28	29	30
30	32	33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	48	49	50
51	52	53	54	55	56	57	58	59	60
	1 11 21 30 41 51	1 2 11 12 21 22 30 32 41 42 51 52	1 2 3 11 12 13 21 22 23 30 32 33 41 42 43 51 52 53	1 2 3 4 11 12 13 14 21 22 23 24 30 32 33 34 41 42 43 44 51 52 53 54	41 42 43 44 45	30 32 33 34 35 36 41 42 43 44 45 46 51 52 53 54 55 56	30 32 33 34 35 36 37 41 42 43 44 45 46 47 51 52 53 54 55 56 57	21 22 23 24 25 26 27 28 30 32 33 34 35 36 37 38 41 42 43 44 45 46 47 48 51 52 53 54 55 56 57 58	21 22 23 24 25 26 27 28 29 30 32 33 34 35 36 37 38 39 41 42 43 44 45 46 47 48 49

# Tissue types\*

The "tissue type" column in the data sheet denotes the following categories.

- 1. normal tissue from a non-cancer patient
- 2. normal tissue from a cancer patient, but the cancer involves unrelated organ
- 3. normal tissue adjacent to the cancer
- 5. tumor of borderline malignancy or uncertain malignant potential
- cancer

# NBP2-30218 - Human Endometrium Tissue MicroArray (Normal)

No.	Age	Sex	Organ	Diagnosis	Associated lesion	Tissue type*
1	35	F	Endometrium	proliferative phase	squamous cell carcinoma of cervix	3
2	39	F	Endometrium	proliferative phase	leiomyoma	1
3	40	F	Endometrium	proliferative phase	squamous cell carcinoma in situ of cervix	3
4	40	F	Endometrium	secretory phase	leiomyoma	1
5	33	F	Endometrium	secretory phase	leiomyoma	1
6	45	F	Endometrium	secretory phase	leiomyoma	1
7	40	F	Endometrium	secretory phase	leiomyoma	1
8	39	F	Endometrium	secretory phase	leiomyoma	1
9	38	F	Endometrium	proliferative phase	endometriosis, ovary	1
10	42	F	Endometrium	secretory phase	leiomyoma	1
11	44	F		secretory phase	leiomyoma	1
12	45	F	Endometrium	secretory phase	leiomyoma	1
13	37	F		secretory phase	leiomyoma	1
14	38	F		proliferative phase	leiomyoma	1
15	42	F		secretory phase	squamous cell carcinoma of cervix	3
16	38	F		proliferative phase	leiomyoma	1
17	37	F		proliferative phase	leiomyoma	1
18	41	F		proliferative phase	leiomyoma	1
19	34	F		secretory phase	squamous cell carcinoma in situ of cervix	3
20	43	F		secretory phase	leiomyoma	1
21	40	F		proliferative phase	leiomyoma	1
22	42	F	Endometrium	secretory phase	leiomyoma	1
23	41	F		proliferative phase	moderate dysplasia of cervix	1
24	45	F		proliferative phase	leiomyoma	1
25	44	F		proliferative phase	leiomyoma	1
26	30	F	Endometrium	secretory phase	squamous cell carcinoma of cervix	3
27	39	F		proliferative phase	leiomyoma	1
28	43	F		secretory phase	leiomyoma	1
29	36	F		proliferative phase	leiomyoma	1
30	44	F		secretory phase	leiomyoma	1
31	42	F		proliferative phase	leiomyoma	1
32	30	F	Endometrium	secretory phase	leiomyoma	1
33	41	F		secretory phase	leiomyoma	1
34	33	F		secretory phase	leiomyoma	1
35	37	F	Endometrium	secretory phase	normal	1
36	29	F		secretory phase	squamous cell carcinoma in situ of cervix	3
37	42	F	Endometrium	secretory phase	leiomyoma	1
38	37	F		proliferative phase	squamous cell carcinoma in situ of cervix	3
39	44 35	F	Endometrium	proliferative phase	leiomyoma	1
40 41	32	F F		proliferative phase	adenomyoma	1
		F		secretory phase	leiomyoma cellular leiomyoma	1
42	36 37	F		secretory phase secretory phase	,	1
43	35	F		secretory phase	leiomyoma leiomyoma	1
45	37	F		secretory phase	squamous cell carcinoma in situ of cervix	3
46	42	F		secretory phase	leiomyoma	1
47	44	F		proliferative phase	leiomyoma	1
48	40	F		proliferative phase	cellular leiomyoma	1
49	35	F		proliferative phase	squamous cell carcinoma of cervix	3
50	36	F		proliferative phase	squamous cell carcinoma of cervix	3
51	35	F		secretory phase	squamous cell carcinoma of cervix	3
52	43	F		secretory phase	squamous cell carcinoma of cervix	3
53	42	F		proliferative phase	leiomyoma	1
54	35	F		proliferative phase	squamous cell carcinoma of cervix	3
55	43	F		secretory phase	leiomyoma	1
56	42	F		secretory phase	squamous cell carcinoma of cervix	3
57	33	F		proliferative phase	leiomyoma	1
58	35	F		proliferative phase	adenomyosis	1
59	45	F	Endometrium	secretory phase	leiomyoma	1
60			Carbon			<u> </u>